急性心力衰竭事件后的心免疫反应模式:AHF-ImmunoCS的设计和第一个结果
Niklas Beyersdorf1, Boshra Afshar1, Dora Pelin2
1Institute for Virology and Immunobiology, University of Würzburg, Würzburg, Germany.
ESC heart failure
|October 30, 2025
概括
在一些患者急性心力衰竭住院后,心脏反应性抗体 (HRA) 在急性心力衰竭住院后很早发展. 这项研究调查了导致HRA的因素及其对心力衰竭预后的影响.
科学领域:
- 免疫学 免疫学 免疫学
- 心脏病学 心脏病学
- 翻译医学是一种翻译医学.
背景情况:
- 心力衰竭 (HF) 的进展可能涉及B细胞和心脏反应性抗体 (HRA).
- 之前的研究表明,HF患者在住院后出现新的HRA时,不良结果增加.
研究的目的:
- 为了研究在急性HF事件后的自适应性免疫反应.
- 识别导致事件HRAs的因素.
- 检查HRA,心脏功能和预后之间的关系.
主要方法:
- 预期单心队列研究 (AHF-ImmunoCS).
- 连续招募急性HF患者,详细表型化.
- 使用免疫光和心脏抗原珠子对HRA进行血清查.
- 随访时间为6周,6个月,12个月,18个月.
主要成果:
- 截至2023年12月,已注册259名患者 (38%为女性,平均年龄为72岁).
- 59名患者的初步数据显示,80%的血清转化到HRA发生在6周内.
- 37%的患者出现了新的HF,LVEF的中位数为50%.
结论:
- AHF-ImmunoCS正在招募一个代表性的HF队列.
- 在一小部分患者中,初步发现证实了HF住院后HRA的早期血清转化.
- 进一步的研究将澄清HRA概况,预后以及急性HF的潜在免疫治疗点.
相关概念视频
Pathophysiology of Heart Failure
2.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.6K
Heart Failure VI: Adjunct Therapies
228
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
228
Heart Failure V: Medical Management
195
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
195
Heart Failure I: Introduction
653
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
653
Heart Failure II: Pathophysiology
658
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
658
Cardiomyopathy II: Dilated Cardiomyopathy
427
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
427


